MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: *Investment Round
Venture Capital: Series D
AqueSys, Inc.
Attachments
AqueSys, Inc.
Parents
*Architects: Ophthalmology, Optometry & Ocular Health (Health IT, Devices & Technology)
*Industry: California (Biomedical)
*Portfolio Companies: Accuitive Medical Ventures
Venture Capital: Series D
Children
Aliso Viejo, California
AqueSys also announced it successfully completed enrollment of their first FDA IDE study, and has begun enrollment of their second FDA approved IDE study utilizing an additional XEN Gel Stent model
AqueSys Inc Wraps Up $43.6 Million Series D Funding (2014)
EN Gel Stent international trials have demonstrated the minimally invasive technology's ability to safely and significantly lower intraocular pressure
Focused on innovating and commercializing implantable devices that will significantly improve the treatment of glaucoma.
Founded 2008
Ron Bache, AqueSys, Inc. President and CEO (2014)
The round was led by a new undisclosed investor with participation from existing investors Accuitive Medical Ventures, The Carlyle Group, Longitude Capital, Rho Ventures, and SV Life Sciences.